PMID- 34943637
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240404
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 11
IP  - 12
DP  - 2021 Dec 20
TI  - A Retrospective Analysis of the Correlation between Functional Imaging and 
      Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3).
LID - 10.3390/diagnostics11122401 [doi]
LID - 2401
AB  - Grade 3 (G3) neuroendocrine tumors (NETs) are a novel category among digestive 
      neuroendocrine neoplasms, characterized by Ki-67 >20% and a well-differentiated 
      morphology, presenting high intra-tumor heterogeneity. We aimed to explore the 
      role of dual-tracer PET imaging ((68)Gallium (Ga)-DOTATOC and 
      (18)Fluorodeoxyglucose (FDG)) as overall survival (OS) predictor in NET G3 
      patients. We performed a retrospective analysis in NET G3 patients treated at our 
      institution between 2003 and 2021. Accordingly, 30 NET G3 patients were analyzed. 
      (68)Ga-DOTA-TOC and (18)F-FDG uptake were assessed by tumor/non-tumor (T-nonT) 
      ratio. We reported a slightly better OS for patients with >/=75% concordance 
      between (68)Ga-DOTA-TOC and (18)F-FDG PET/CT (p = 0.42). Among patients with 
      discordant functional imaging, we reported a better 5-y OS rate for patients with 
      a prevalent (68)Ga-DOTATOC vs. (18)F-FDG PET/CT (p = 0.016). In positive 
      (18)F-FDG PET/CT cases, we reported a better OS for <4 vs. >/=4 T/non-T ratio (p = 
      0.021). Among upfront-NET G3 patients with concordant exams, 5-y OS rate was 
      83.3% (95% CI: 27.3-97.5). Among patients with discordant exams, 5-y OS rate was 
      81.3% (52.5-93.5), 100% for those with prevalent receptor expression, and 50% 
      (11.1-80.4) for those with prevalent (18)F-FDG uptake. Our findings suggest that 
      dual-tracer PET/CT can be considered as a predictor of patient outcome, able to 
      stratify NET G3 patients with poorer prognosis.
FAU - Laffi, Alice
AU  - Laffi A
AUID- ORCID: 0000-0001-7458-3366
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European 
      Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Colandrea, Marzia
AU  - Colandrea M
AD  - Division of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via 
      Ripamonti 435, 20141 Milan, Italy.
FAU - Buonsanti, Giuseppe
AU  - Buonsanti G
AD  - Division of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via 
      Ripamonti 435, 20141 Milan, Italy.
FAU - Frassoni, Samuele
AU  - Frassoni S
AD  - Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 
      20126 Milan, Italy.
FAU - Bagnardi, Vincenzo
AU  - Bagnardi V
AD  - Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 
      20126 Milan, Italy.
FAU - Spada, Francesca
AU  - Spada F
AUID- ORCID: 0000-0003-3642-0798
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European 
      Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Pisa, Eleonora
AU  - Pisa E
AD  - Division of Pathology and Laboratory Medicine, European Institute of Oncology 
      (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Barberis, Massimo
AU  - Barberis M
AUID- ORCID: 0000-0002-0943-4804
AD  - Division of Pathology and Laboratory Medicine, European Institute of Oncology 
      (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Rubino, Manila
AU  - Rubino M
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European 
      Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
FAU - Grana, Chiara Maria
AU  - Grana CM
AD  - Unit of Radiometabolic Therapy, European Institute of Oncology (IEO), IRCCS, Via 
      Ripamonti 435, 20141 Milan, Italy.
FAU - Ceci, Francesco
AU  - Ceci F
AD  - Division of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via 
      Ripamonti 435, 20141 Milan, Italy.
FAU - Fazio, Nicola
AU  - Fazio N
AUID- ORCID: 0000-0001-6869-0704
AD  - Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European 
      Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20211220
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC8700454
OTO - NOTNLM
OT  - 18F-FDG
OT  - 68Ga
OT  - NET G3
OT  - PET/CT
OT  - neuroendocrine
COIS- The authors declare no conflict of interest.
EDAT- 2021/12/25 06:00
MHDA- 2021/12/25 06:01
PMCR- 2021/12/20
CRDT- 2021/12/24 01:03
PHST- 2021/11/11 00:00 [received]
PHST- 2021/12/13 00:00 [revised]
PHST- 2021/12/17 00:00 [accepted]
PHST- 2021/12/24 01:03 [entrez]
PHST- 2021/12/25 06:00 [pubmed]
PHST- 2021/12/25 06:01 [medline]
PHST- 2021/12/20 00:00 [pmc-release]
AID - diagnostics11122401 [pii]
AID - diagnostics-11-02401 [pii]
AID - 10.3390/diagnostics11122401 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2021 Dec 20;11(12):2401. doi: 10.3390/diagnostics11122401.